Articles tagged "Immunosuppression"

2018 American Transplant Congress
Prolonged-Release Tacrolimus Dosing in De Novo Kidney Transplantation: Randomized, Open-Label, Pilot Study
Y. Kim,¹ Y. Chiang,² S. Kim,³ M. Kim,⁴ S. Park,⁵ S. Wu,⁶ K. Horita,⁷ Y. Nakashima,⁷ H. Jiang,⁸ D. Han.¹
¹Asan Medical Center, Seoul, Korea; ²Chang Gung Memorial Hospital-Linkou, Taoyuan City, Taiwan; ³Samsung Medical Center, Seoul, Korea; ⁴Severance Hospital, Seoul, Korea; ⁵Dongsan Medical Center, Daegu, Korea; ⁶Tri-Service General Hospital, Taipei City, Taiwan; ⁷Astellas Pharma, Inc., Tokyo, Japan; ⁸Astellas Pharma, Inc., Maao, Singapore.
A multicenter, randomized, open-label, parallel-group, pilot, 52-wk study in Asian countries that assessed renal function, efficacy, and safety of low vs standard-dose prolonged-release tacrolimus (PRT)…
2018 American Transplant Congress
Regulation of NK Cell Cytotoxicity by TEC Expression of Clr Proteins in Kidney Ischemia Reperfusion Injury (IRI)
B. Fuhrmann,^1,5 D. Lian,⁵ Z. Yin,⁵ S. Ma,^4,5 J. Arp,⁵ Z. Zhang,^2,3,4,5 A. Jevnikar.^1,3,4,5
¹Microbiology and Immunology, Western University, London, Canada; ²Pathology, Western University, London, Canada; ³Medicine, Western University, London, Canada; ⁴Multi-Organ Transplant Program, London Health Sciences Centre, London, Canada; ⁵Matthew Mailing Centre for Translational Transplant Studies, London Health Sciences Centre, London, Canada.
Background: Kidney tubular epithelial cells (TEC) may negatively regulate NK cell activation and cytotoxic capacity by surface expression of a novel class of C-type lectin-related…
2018 American Transplant Congress
High Calcineurin Inhibitor Intra Patient Variability is Associated with Early Renal Allograft Inflammation, Chronicity and Loss
A. Sharma,¹ A. Cherukuri,² R. Mehta,¹ P. Sood,¹ S. Hariharan.¹
¹Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA.
High CNI IPV has been associated with poor kidney allograft outcomes, albeit in small limited studies. We evaluated effect of CNI IPV (the degree of…
2018 American Transplant Congress
Steroid Sparing Maintenance Immunosuppression is Associated with Decreased Mortality after Simultaneous Liver Kidney Transplantation
S. Weeks, X. Luo, C. Song, L. Pote, A. Gurakar, F. Navqi, B. Philosophe, A. Cameron, N. Desai, S. Ottmann, D. Segev, J. Garonzik Wang.
Johns Hopkins, Baltimore, MD.
Purpose: Significant variation in maintenance immunosuppression (mIS) regimens has been described between transplant centers for simultaneous liver kidney (SLK) transplant recipients; we sought to describe…
2018 American Transplant Congress
Individualized Immunosuppression through Risk-Stratification in Renal Transplantation Preserves Excellent Outcomes at Three Years
J. Dann, A. Agarwal, M. Bradley, J. Geyston, W. Ally.
University of Virginia Health System, Charlottesville, VA.
Risk-stratification of renal transplant recipients based on immunologic risk factors allows for tailored immunosuppression (IS), but long term follow up is limited. This study evaluates…
2018 American Transplant Congress
Development of Denovo DSA after One Year Post Kidney Transplant and Clinical Outcomes in Patient on Steroid Free Immunosupression
A. Sharfuddin, M. Yaqub, D. Mishler, W. Goggins, T. Taber, O. Adebiyi.
Division of Renal Disease and Hypertension, Indiana University Health Transplant Program, Indianapolis, IN.
Background: Development of Denovo donor specific antibodies (DnDSA) has been associated with poor allograft outcomes in few studies. However, there is scarcity of data evaluating…
2018 American Transplant Congress
Delayed Graft Function in Live Donor HLA-Incompatible Kidney Transplant Recipients: A Multicenter Study
J. Motter,¹ A. Massie,¹ J. Garonzik Wang,¹ K. Jackson,¹ X. Luo,¹ A. Muzaale,¹ B. Orandi,² D. Segev.¹
¹JHU, Baltimore; ²UCSF, San Francisco.
Background: Many patients with a willing, but incompatible live donor choose to undergo incompatible live donor kidney transplantation (ILDKT) facilitated by desensitization procedures to eliminate…
2018 American Transplant Congress
Ideal Body Weight versus Actual Body Weight for Rabbit Antithymocyte Globulin Induction in Pancreas Transplantation
E. Martinez,¹ D. Felix,² J. Wiegel,² T. Al-Qaoud,¹ G. Leverson,¹ A. Condon,² R. Redfield,¹ J. Odorico.¹
¹Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI; ²Department of Pharmacy, UW Health, Madison, WI.
Purpose: Rabbit antithymocyte globulin (rATG) is the most commonly used induction agent in solid organ pancreas transplantation. The optimal induction dosing of rATG, has not…
2018 American Transplant Congress
Outcomes Associated with Rabbit Anti-Thymocyte Globulin Induction According to Mg/Kg of Total Body Weight in Kidney Transplant Recipients
A. Brueckner, A. Logan, L. Bowman.
Pharmacy, Tampa General Hospital, Tampa, FL.
Purpose: The optimal dosing weight used for rabbit anti-thymocyte globulin (rATG) induction therapy in transplantation continues to lack a consensus. The impact of alternative dosing…
2018 American Transplant Congress
The Impact of Rapamycin Conversion in Pediatric Liver Transplantation on Anti-HLA Antibody Formation and Allograft Fibrosis
R. Fischer,² L. Fromm,¹ J. Daniel,² A. Kats,² R. Hendrickson,² W. Andrews.²
¹University of Kansas College of Medicine, Kansas City, KS; ²Children's Mercy Hospital, Kansas City, MO.
Background: Maintenance immunosuppression with tacrolimus (TAC) is associated with progressive liver allograft fibrosis. Conversion to rapamycin (RAPA) may abrogate this progression. The development of donor-specific…